A Multi-center, Open-label, Single-arm Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
Sanofi
Summary
This is a multinational, open label, single arm study that will evaluate the impact of early multi-immune modulation with rilzabrutinib in adult ITP patients who failed first-line treatment. The study includes a screening period (up to 8 weeks), a primary analysis period (up to 28 weeks), a long-term extension period for selected participants (28 weeks) and a 24-week follow-up period only for eligible participants.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Key Inclusion Criteria: * Male or female participants aged 18 years and older with a documented diagnosis of primary ITP in the medical history * Participant received at least one course of first-line therapy and had a history of response while on treatment * Participant has loss of response, relapse, or steroid dependency Key Exclusion Criteria: * Participants with Secondary ITP * Participants with Evans syndrome or history of myelodysplastic syndrome * Participants with history of lymphoma, leukemia, or any malignancy within the past 5 years except for non-melanoma skin malignancy. * Part…
Interventions
- Drugrilzabrutinib
Pharmaceutical form:Tablet-Route of administration:Oral
Locations (24)
- Tulane University Health Sciences Center - Tulane Avenue-Investigational Site Number: 8400011New Orleans, Louisiana
- University of Michigan Health - Michigan Medicine - University Hospital-Investigational Site Number: 8400001Ann Arbor, Michigan
- Mayo Clinic_Investigational Site Number: 8400009Rochester, Minnesota
- New York Oncology Hematology-Investigational Site Number: 8400010Albany, New York
- Montefiore Medical Center-Investigational Site Number: 8400012The Bronx, New York
- Community Cancer Trials of Utah-Investigational Site Number: 8400002Ogden, Utah